rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
12
|
pubmed:dateCreated |
2009-10-5
|
pubmed:abstractText |
To evaluate anti-IgE (ie, omalizumab) efficacy on severe allergic asthma in order to achieve the efficacy of this treatment on severe allergic asthma progress by means of asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ) as well as pulmonary function (FEV1) and physician overall assessment.
|
pubmed:language |
spa
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0025-7753
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
3
|
pubmed:volume |
133
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
460-3
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:19775710-Adolescent,
pubmed-meshheading:19775710-Adrenal Cortex Hormones,
pubmed-meshheading:19775710-Adult,
pubmed-meshheading:19775710-Aged,
pubmed-meshheading:19775710-Anti-Asthmatic Agents,
pubmed-meshheading:19775710-Antibodies, Anti-Idiotypic,
pubmed-meshheading:19775710-Antibodies, Monoclonal,
pubmed-meshheading:19775710-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19775710-Asthma,
pubmed-meshheading:19775710-Data Interpretation, Statistical,
pubmed-meshheading:19775710-Female,
pubmed-meshheading:19775710-Humans,
pubmed-meshheading:19775710-Male,
pubmed-meshheading:19775710-Middle Aged,
pubmed-meshheading:19775710-Quality of Life,
pubmed-meshheading:19775710-Questionnaires,
pubmed-meshheading:19775710-Skin Tests,
pubmed-meshheading:19775710-Time Factors,
pubmed-meshheading:19775710-Treatment Outcome
|
pubmed:year |
2009
|
pubmed:articleTitle |
[Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
|
pubmed:affiliation |
Servicio de Neumología, Hospital Ramón y Cajal, Madrid, Spain. apacheco.hcr@salud.madrid.org
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract
|